TECH
Bio-Techne Corp
NASDAQ: TECH · HEALTHCARE · BIOTECHNOLOGY
$51.95
-2.92% today
Updated 2026-04-29
Market cap
$8.13B
P/E ratio
98.02
P/S ratio
6.69x
EPS (TTM)
$0.53
Dividend yield
0.60%
52W range
$46 – $72
Volume
2.2M
WallStSmart proprietary scores
48
out of 100
Grade: C
Sell
Investment rating
4.0
Growth
C7.3
Quality
B+5.5
Profitability
C+6.7
Valuation
B3/9
Piotroski F-Score
Weak
3.2
Altman Z-Score
Safe zone
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$72.27
+39.11%
12-Month target
$11.32
-78.21%
Intrinsic (DCF)
$212.04
Margin of safety
+70.08%
1 Strong Buy9 Buy4 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Altman Z 3.20 — safe zone
+ Free cash flow $76.49M — positive
+ 70.08% below intrinsic value
Risks
- Piotroski 3/9 — weak financial health
- Revenue declining -0.40% QoQ
- P/E 98.02x — expensive valuation
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $1.11B | $1.14B | $1.16B | $1.22B | $1.22B |
| Net income | $272.05M | $285.26M | $168.10M | $73.40M | $38.01M |
| EPS | — | — | — | — | $0.53 |
| Free cash flow | $280.36M | $216.15M | $236.10M | $256.55M | $76.49M |
| Profit margin | 24.61% | 25.10% | 14.50% | 6.02% | 6.67% |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-04-14 | KELDERMAN, KIM | Sale | 36,500 | — |
| 2026-04-14 | KELDERMAN, KIM | Buy | 36,500 | — |
| 2026-04-14 | KELDERMAN, KIM | Sale | 32,088 | $58.66 |
Peer comparison
Smart narrative
Bio-Techne Corp trades at $51.95. representing a P/E of 98.02x trailing earnings. Our Smart Value Score of 48/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 3.20, it sits in the safe zone. TTM revenue stands at $1.22B. with profit margins at 6.67%. Our DCF model estimates intrinsic value at $212.04.
Frequently asked questions
What is Bio-Techne Corp's stock price?
Bio-Techne Corp (TECH) trades at $51.95.
Is Bio-Techne Corp overvalued?
Smart Value Score 48/100 (Grade C, Sell). DCF value $212.04.
What is the price target of Bio-Techne Corp (TECH)?
The analyst target price is $72.27, representing +39.1% upside from the current price of $51.95.
What is the intrinsic value of Bio-Techne Corp (TECH)?
Based on our DCF model, intrinsic value is $212.04, a +70.1% margin of safety versus $51.95.
What is Bio-Techne Corp's revenue?
TTM revenue is $1.22B.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
3.20 — safe zone.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio6.69x
ROE3.97%
Beta1.49
50D MA$54.90
200D MA$58.10
Shares out0.16B
Float0.15B
Short ratio—
Avg volume2.2M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—